Genomtec submits a prospectus to KNF

Genomtec, a company from the medical technology industry listed on NewConnect, submitted to the Polish Financial Supervision Authority (KNF) an issue prospectus drawn up in connection with the planned transfer of the company's shares to the main market of the Warsaw Stock Exchange. The main motivation of the Company to transfer the listing is to increase the recognition of the Company and gain access to a larger group of long-term investors, including foreign investors.

"The transfer of stock quotes to the main market will be another step in our long-term strategy. The company is steadily growing, our key product, GenomtecID, is in the final stage of development, so we felt it was the right time to change the trading floor. We believe that Genomtec is a valuable company, and the transfer of shares will increase our recognition not only among the largest institutional investors in Poland but will also open the door to foreign investors. We want to build a stable shareholder structure because projects in the MedTech industry are long-term, and the stability will facilitate our work on commercializing new solutions for patients and the healthcare system," Miron Tokarski, chairman of the board and co-founder of Genomtec, said.

(WBJ)